Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics, Inc. (BDTX)
:BDTX
BDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $6.75
Previous CloseN/A
Volume170.82K
Average Volume (3M)1.11M
Market Cap
$155.23M
Enterprise Value-$41.42M
Total Cash (Recent Filing)$152.40M
Total Debt (Recent Filing)$21.59M
Price to Earnings (P/E)43.6
Beta2.27
Next Earnings
Nov 10, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding56,862,637
10 Day Avg. Volume775,048
30 Day Avg. Volume1,108,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.27
Enterprise Value/Revenue-0.59
Enterprise Value/Gross Profit-0.59
Enterprise Value/Ebitda11.31
Forecast
1Y Price Target
$11.00Price Target Upside288.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Drug EfficacyBDTX-1535 shows clear evidence of activity post-osimertinib, which could translate favorably to the 1L setting, particularly in patients with non-classical mutations where osimertinib is less active.
Financial StrengthThe company is well capitalized, with sufficient funding to support a first-line NSCLC study in non-classical mutations.
Market OpportunityThe company is focusing efforts on the lucrative opportunity in 1L non-classical/PACC EGFR mutations, which presents a potentially larger market.
Bears Say
Competitive LandscapeThe evolving competitive landscape in 2L NSCLC presents challenges and a modest commercial opportunity.
Regulatory ChallengesManagement plans to use the emerging 1L data to meet with regulators regarding a registrational path forward in 1L, leading to a regulatory update for investors.
Black Diamond Therapeutics News
BDTX FAQ
What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?
Black Diamond Therapeutics, Inc. lowest stock price was $1.20 and its highest was $6.75 in the past 12 months.
What is Black Diamond Therapeutics, Inc.’s market cap?
Black Diamond Therapeutics, Inc.’s market cap is $155.23M.
When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?
Black Diamond Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 94 days.
How were Black Diamond Therapeutics, Inc.’s earnings last quarter?
Black Diamond Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.058.
Is Black Diamond Therapeutics, Inc. overvalued?
According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued.
Does Black Diamond Therapeutics, Inc. pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
What is Black Diamond Therapeutics, Inc.’s EPS estimate?
Black Diamond Therapeutics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc. has 56,862,637 shares outstanding.
What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?
Black Diamond Therapeutics, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went up 10.286%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BDTX
Black Diamond Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (288.69% Upside)
$11.00 (288.69% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 555.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.25%
12-Months-Change
Fundamentals
Return on Equity
4.14%
Trailing 12-Months
Asset Growth
23.66%
Trailing 12-Months
Company Description
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
BDTX Stock 12 Month Forecast
Average Price Target
$11.00
▲(288.69% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Galectin Therapeutics
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Instil Bio
―
Ownership Overview
24.77% Insiders
17.16% Mutual Funds
0.27% Other Institutional Investors
52.81% Public Companies and Individual Investors
Options Prices
Currently, No data available
---